JBIO Company Profile and Key Details

JBIO has shown sold momentum, gaining 10.03% over the past week and 62.75% over the past quarter, though year-to-date performance is down -1.17%. Short-term trend indicators are mixed aligned (SMA20 -2.42%, SMA50 -3.69%, SMA200 38.26%). The stock’s 14-day RSI is 48.59 (neutral), while the ATR of 1.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.79% below its high and over 121.78% above its low. Average 10-day trading volume of 1.22 million shares is slightly above the 3-month average of 917.05 thousand, indicating heightened recent market interest.

Jade Biosciences, Inc. has 63.60 million shares outstanding. The public float is 51.97 million shares, elevated short interest at 16.74% of float. This equals 8.69 million shares. The short ratio is 9.61 days. Institutional investors hold 96.98% of the float. Insiders own 0.83%.

Jade Biosciences, Inc. generated EPS of -$11.36 over the past year. Five-year average earnings growth is -77.98%. Wall Street analysts project EPS growth of 69.31% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $74.00 to $17.00. The high target offers 413.18% upside. The low target suggests 17.89% downside. The mean target is $36.56. This offers 153.54% upside. Jade Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended August 10, 2026, missed forecasts by 19.42%. The prior quarter beat by 9.62%. Over the last six quarters, Apple has recorded several small beats. These include -98.93% in April 25, 2025.

Jade Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.80. This means the shares are trading above this model’s fair value.

Jade Biosciences, Inc. (NASDAQ:JBIO) closed at $14.42 USD, losing -$0.31 (-2.10%) from the previous close of $14.73. The stock is currently mid-range between its 52-week high and low $8.16 and $28.00. With a market capitalization of about $877.60 million, Jade Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.45). Key stats such as the average daily volume over the past year has been around 913.37 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Jade Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tom Frohlich, the company employs approximately 55 people and listed since June 30, 2021. Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.

Jade Biosciences, Inc. trades at a P/E ratio of -5.24, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.0 suggesting the stock is closer to book value. The P/FCF stands at -7.1, also below market averages.

Jade Biosciences, Inc. (NASDAQ:JBIO) shares are flat -1.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Jade Biosciences, Inc. trading at a premium to the broader market with a P/E of -5.24. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $34.28, suggesting 137.73% upside. Our AI forecast model points to short-term weakness (-20.94% over two weeks), a medium-term rise (90.71% over three months), and a longer-term gain (41.47% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Jade Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -20.94%, with price expected at $11.40 by October 09, 2026, within a range of $10.49 to $12.31 3-Month Outlook: Projected rise of 90.71%, reaching $27.50 by December 24, 2026, with a range of $27.19 to $27.82. 1-Year Outlook: Projected gain of 41.47%, with price at $20.40 by September 24, 2027, within a range of $20.15 to $20.62.